Laura van ‘t Veer, PhD, is one of the world’s leading innovators in cancer diagnostics and is widely recognized as a pioneer in the field of personalized medicine. She co-founded Agendia as spin-off from the Netherlands Cancer Institute in 2003 and launched the MammaPrint® test. She is Professor at the University California San Francisco.
Laura van ‘t Veer discovered a specific 70-gene activity signature named MammaPrint which can distinguish whether breast cancers have a low or high risk of recurrence. About half of breast cancer patients who would be recommended chemotherapy based on traditional factors can now safely forego this treatment, impacting over 50,000 patients in Europe per year. She received the 2014 European Union Women Innovators Award second prize; the 2015, European Patent Office (EPO) European Inventor Award for small and medium enterprises; and in 2017 the European CanCer Organization (ECCO) Clinical Research Award.